S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:SVRA

Savara Stock Forecast, Price & News

$1.45
+0.09 (+6.62 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.30
Now: $1.45
$1.48
50-Day Range
$1.15
MA: $1.30
$1.47
52-Week Range
$1.00
Now: $1.45
$3.95
Volume759,671 shs
Average Volume396,804 shs
Market Capitalization$78.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Savara logo

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

256th out of 1,558 stocks

Pharmaceutical Preparations Industry

135th out of 638 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-614-1848
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$6.30 per share
Book Value$2.47 per share

Profitability

Net Income$-78,170,000.00

Miscellaneous

Market Cap$78.50 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$1.45
+0.09 (+6.62 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock price been impacted by COVID-19?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SVRA shares have decreased by 38.6% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19
.

Is Savara a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Savara wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Savara
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business had revenue of $0.26 million for the quarter.
View Savara's earnings history
.

What price target have analysts set for SVRA?

2 equities research analysts have issued twelve-month price targets for Savara's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Savara's stock price to reach $3.00 in the next year. This suggests a possible upside of 106.9% from the stock's current price.
View analysts' price targets for Savara
or view Wall Street analyst' top-rated stocks.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.45.

How big of a company is Savara?

Savara has a market capitalization of $78.50 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.